Rachel C Jankowitz

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. pmc A Putative Case of Methotrexate-Related Lymphoma: Clinical Course and PET/CT Findings
    Rachel C Jankowitz
    Department of Oncology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Case Report Med 2009:469343. 2009
  2. ncbi request reprint Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer
    Rachel C Jankowitz
    University of Pittsburgh Cancer Institute and UPMC Cancer Center, USA Electronic address
    Breast 22:S165-70. 2013
  3. pmc Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term
    Rachel C Jankowitz
    University of Pittsburgh Cancer Institute, Magee Women s Hospital, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Breast Cancer Res 14:308. 2012
  4. pmc Epigenetics in breast cancer: what's new?
    Yi Huang
    University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Breast Cancer Res 13:225. 2011
  5. pmc Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer
    Rachel C Jankowitz
    Department of Medicine, Division of Hematology Oncology, UPMC, University of Pittsburgh Cancer Institute, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Breast Cancer Res 13:R98. 2011

Collaborators

Detail Information

Publications5

  1. pmc A Putative Case of Methotrexate-Related Lymphoma: Clinical Course and PET/CT Findings
    Rachel C Jankowitz
    Department of Oncology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Case Report Med 2009:469343. 2009
    ..Conclusion. Withdrawal of MTX in a patient with lymphoma is reasonable before initiating chemotherapy, but observation for early regrowth of disease is necessary...
  2. ncbi request reprint Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer
    Rachel C Jankowitz
    University of Pittsburgh Cancer Institute and UPMC Cancer Center, USA Electronic address
    Breast 22:S165-70. 2013
    ..Nonetheless, the need for other predictive biomarkers to select appropriate therapy remains real. Finally, attention to long term benefits and side effects of therapy will continue to be vital for these young women. ..
  3. pmc Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term
    Rachel C Jankowitz
    University of Pittsburgh Cancer Institute, Magee Women s Hospital, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Breast Cancer Res 14:308. 2012
    ..Ongoing study is needed to identify markers of resistance to trastuzumab and incorporate newer agents in the adjuvant setting in order to further decrease rates of distant recurrence and death from HER2-positive breast cancer...
  4. pmc Epigenetics in breast cancer: what's new?
    Yi Huang
    University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Breast Cancer Res 13:225. 2011
    ....
  5. pmc Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer
    Rachel C Jankowitz
    Department of Medicine, Division of Hematology Oncology, UPMC, University of Pittsburgh Cancer Institute, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
    Breast Cancer Res 13:R98. 2011
    ..Objectives of the current study were to validate BCI in a clinical case series and to compare the prognostic utility of BCI and Adjuvant!Online (AO)...